How Investors May Respond To Halozyme Therapeutics (HALO) Mixed Q4 Results And ENHANZE-Focused Guidance Shift
Halozyme Therapeutics reported mixed Q4 2025 results with revenue exceeding expectations but earnings falling short. Despite this, the company reiterated its 2026 revenue guidance and highlighted growing royalty revenues and expanding ENHANZE partnerships as key drivers. Analysts remain optimistic about Halozyme's ENHANZE-driven growth, projecting significant revenue and earnings increases by 2029, suggesting a potential 31% upside to its current price.
Halozyme Therapeutics Insider Sold Shares Worth $2,592,237, According to a Recent SEC Filing
A recent SEC filing revealed that an insider at Halozyme Therapeutics sold shares totaling $2,592,237. This news, published on April 6, 2026, highlights internal financial activity at the biopharmaceutical company. Halozyme Therapeutics specializes in drug delivery technology and combination products, with commercial products like Hylenex and XYOSTED.
HALO: Future Upside Will Depend On Expanding ENHANZE And Hypercon Pipeline Deals
Analysts are re-evaluating Halozyme Therapeutics (HALO) with mixed sentiment, raising price targets due to strong Q4 results, increased royalty expectations from ENHANZE partnerships, and new deals like Entyvio. However, concerns remain regarding the long-term durability of ENHANZE royalties, the lower royalty rate for the Entyvio agreement, and the need for continued progress in next-generation subcutaneous technologies. The company is actively pursuing acquisitions and aims for at least three new licensing agreements in 2026, while also having completed a significant share buyback program.
Tema Etfs LLC Invests $1.7M in Halozyme Therapeutics
Tema Etfs LLC has invested $1.7 million in Halozyme Therapeutics, purchasing 25,256 shares of the biopharmaceutical company in Q4 2025. This move signals confidence in Halozyme's growth potential and its innovative ENHANZE® technology, which facilitates subcutaneous administration of biologic therapies. The investment highlights a growing interest in companies focused on improving drug delivery and patient convenience within the evolving biotech industry.
Tema Etfs LLC Makes New $1.70 Million Investment in Halozyme Therapeutics, Inc. $HALO
Tema Etfs LLC has invested $1.70 million in Halozyme Therapeutics by purchasing 25,256 shares in the fourth quarter, increasing institutional ownership to 97.79%. This occurred despite Halozyme missing Q4 EPS estimates, though revenue exceeded expectations. Insider selling has been noted, with CEO Helen Torley and other insiders selling shares recently.
Halozyme Therapeutics CEO sells $2.59 million in stock By Investing.com
Halozyme Therapeutics CEO Helen Torley sold 39,000 shares of common stock for approximately $2.59 million on April 1st and 2nd, 2026, while also exercising options to acquire 40,000 shares. Despite the insider sale, InvestingPro analysis suggests the stock is undervalued, boasting a strong return on equity and a P/E ratio of 24.91. These transactions occurred amidst significant news for the company, including a 52% increase in Q4 revenue, an interim CFO appointment, and FDA approval for a Johnson & Johnson therapy involving Halozyme's DARZALEX FASPRO.
Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) CEO Sells 20,000 Shares of Stock
Halozyme Therapeutics (NASDAQ:HALO) CEO Helen Torley sold 20,000 shares of the company's stock on April 2nd, valued at $1,284,800. This sale, conducted under a pre-arranged Rule 10b5-1 plan, reduced her ownership by 2.54%. Despite missing EPS estimates, Halozyme exceeded revenue expectations with strong year-over-year growth, and analysts generally maintain a "Hold" rating with an average price target of $78.56.
Halozyme (NASDAQ: HALO) CEO exercises 40k options, sells 40k shares
Halozyme (NASDAQ: HALO) President and CEO Helen Torley exercised options to acquire 40,000 shares of common stock at an exercise price of $12.07 per share and subsequently sold all 40,000 shares in open-market transactions at prices ranging from $64.0630 to $65.7140. These transactions, which occurred on April 1-2, 2026, were conducted under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, Torley directly owned 767,780 shares of Halozyme common stock.
Is Halozyme Therapeutics (HALO) Pricing Reflect Its Potential After Recent Share Price Pullback
This article analyzes Halozyme Therapeutics (HALO) valuation following a recent share price pullback. Using a Discounted Cash Flow (DCF) model, Simply Wall St suggests HALO is significantly undervalued, while a Price-to-Earnings (P/E) ratio comparison indicates it's overvalued relative to its industry and peers. The analysis also presents bull and bear case narratives, offering different perspectives on the company's future potential.
Is Halozyme Therapeutics (HALO) Pricing Reflect Its Potential After Recent Share Price Pullback
Halozyme Therapeutics (HALO) has experienced a recent share price pullback, leading to a valuation analysis. A Discounted Cash Flow (DCF) analysis suggests the stock is significantly undervalued by 70.3%, with an estimated intrinsic value of $209.00 per share compared to its current price of $62.13. However, its P/E ratio of 23.23x, compared to an industry average of 14.83x and a "Fair Ratio" of 19.93x, indicates it might be overvalued based on earnings.
Halozyme Therapeutics (HALO) appoints interim CFO amid growth plans
Halozyme Therapeutics has appointed Nicole Laakso as its interim Chief Financial Officer, effective immediately. This appointment comes as the company continues to execute its growth strategy, leveraging its ENHANZE drug delivery technology. The company highlighted Ms. Laakso's extensive experience and leadership qualities as valuable assets during this transition.
Halozyme to Report Second Quarter 2025 Financial and Operating Results
Halozyme Therapeutics, Inc. announced it will release its second-quarter 2025 financial and operating results on Tuesday, August 5, 2025, after the market closes. The company will host a conference call on the same day at 1:30 p.m. PT / 4:30 p.m. ET to discuss these results, with access available via a pre-registration link, live webcast, and replay on its corporate website. Halozyme is a biopharmaceutical company known for its ENHANZE® drug delivery technology and its focus on developing drug-device combination products.
Halozyme Therapeutics (HALO) Appoints Interim CFO Amid Growth Plans
Halozyme Therapeutics (HALO) has appointed David Ramsay as interim CFO, who previously served in the role from 2003-2009 and 2013-2015, during which the company grew significantly. This appointment comes as Halozyme outlines an ambitious growth strategy, projecting $1.7–$1.8 billion in revenue for the year and aiming for 40 drugs approved or in development by 2028, largely driven by its ENHANZE and Hypercon technologies. The company forecasts adjusted EBITDA of $1.1–$1.2 billion and plans at least three new deals in 2026, despite ongoing patent litigation with Merck.
Record revenue and royalties fail to lift Halozyme Therapeutics stock amid sustained technical weakness
Despite reporting record full-year 2025 revenue of $1.4 billion and projecting $1.71-$1.81 billion for 2026, Halozyme Therapeutics (HALO) stock is facing significant technical weakness. The company's shares are trading well below key moving averages, indicating strong selling pressure, with high probability of further declines. The expected trading range for the coming week is $59.00 to $64.50, and a bullish reversal would require a move above $66.88.
Assenagon Asset Management Acquires Stake in Halozyme Therapeutics
Assenagon Asset Management S.A. has acquired a new position in Halozyme Therapeutics, purchasing 72,085 shares valued at approximately $4.85 million. This investment signifies confidence in Halozyme's growth potential and drug pipeline, particularly its ENHANZE® technology. The move by the European asset manager comes as other institutional investors also increase their stakes in the biopharmaceutical company.
Assenagon Asset Management S.A. Takes Position in Halozyme Therapeutics, Inc. $HALO
Assenagon Asset Management S.A. has acquired a new position in Halozyme Therapeutics (NASDAQ:HALO), purchasing 72,085 shares valued at approximately $4.85 million. This investment brings institutional ownership of Halozyme to 97.79%. Despite a recent EPS miss, the company's Q4 revenue grew by 51.6% year-over-year to $451.8 million, though analysts maintain a "Hold" consensus rating with a target price of $78.56.
Halozyme Therapeutics Inc Stock Historical Valuations | HAM:RV7
This article provides key financial valuation metrics for Halozyme Therapeutics Inc (HAM:RV7), including its P/E ratio, P/B ratio, market capitalization, and enterprise value. It also notes a severe warning sign detected by GuruFocus for the company. The page is part of GuruFocus.com, a platform offering various stock analysis tools and data.
5 Most Undervalued Growth Stocks to Buy According to Analysts
The article identifies Halozyme Therapeutics (NASDAQ:HALO) as one of the most undervalued growth stocks, according to analysts. It highlights Halozyme's recent appointment of an interim CFO and its ambitious growth strategy, projecting significant revenue increases and expanded product offerings by 2028. Despite patent litigation, the company anticipates strong royalty revenues and further development in its drug delivery technologies.
A Look At Halozyme Therapeutics (HALO) Valuation After Mixed Quarterly Earnings And Guidance
Halozyme Therapeutics (HALO) reported mixed quarterly results with revenue up 51.6% but EPS missing estimates and full-year guidance falling short, causing a recent 10.05% stock price decline. Despite this, a common narrative suggests the stock is 25.1% undervalued, with a fair value of $84.50, largely due to the accelerating adoption of its ENHANZE drug delivery platform. However, the current P/E ratio is higher than peers, indicating potential risk if growth expectations are not met.
Halozyme Therapeutics prices $1.3 billion convertible notes
Halozyme Therapeutics has priced $1.3 billion in convertible senior notes due in 2029. The initial purchasers have a 13-day option to buy an additional $150 million worth of notes. This offering is a significant financial move for the company.
Vanguard realignment reports zero Halozyme holdings (NASDAQ: HALO)
Vanguard Group has filed an amended Schedule 13G/A, reporting zero beneficial ownership of Halozyme Therapeutics (NASDAQ: HALO) common stock, representing 0% of the class. This change is due to an internal realignment within Vanguard, where certain subsidiaries will now report their holdings separately, rather than an actual sale of Halozyme shares. The filing clarifies that this is a procedural change based on SEC guidance for disaggregated reporting.
A Look At Halozyme Therapeutics (HALO) Valuation After Mixed Quarterly Earnings And Guidance
Halozyme Therapeutics (HALO) recently reported mixed quarterly results with revenue exceeding expectations but EPS missing forecasts and full-year guidance falling short, causing a 10.05% decline in its share price over 30 days. Despite this, the company is still considered 25.1% undervalued by analysts, with a fair value target of $84.50 thanks to its ENHANZE platform's role in the shift towards subcutaneous drug delivery. However, its P/E ratio of 23.7x is higher than peers, suggesting potential risks if growth or margins don't meet expectations.
Is Halozyme’s Interim CFO Appointment Shaping The ENHANZE Royalty Story For Halozyme Therapeutics (HALO)?
Halozyme Therapeutics recently appointed David Ramsay as Interim CFO to oversee financial operations. Ramsay's long history with the company and capital markets experience are seen as providing continuity, particularly as Halozyme expands its ENHANZE partnerships and seeks new licensing deals. While the appointment is viewed as a continuity move, investors are advised to consider the potential for ENHANZE patent challenges and the company's dependency on a few blockbuster partners.
Congress Asset Management Co. Cuts Position in Halozyme Therapeutics, Inc. $HALO
Congress Asset Management Co. reduced its stake in Halozyme Therapeutics (NASDAQ:HALO) by 9.4% in the fourth quarter of 2025, selling 134,353 shares. Despite this, institutional investors collectively own 97.79% of the company, with various hedge funds initiating or increasing their positions. The company reported a Q4 EPS miss but saw significant revenue growth, while analysts hold a "Hold" rating with an average target of $78.56.
Congress Asset Management Co. Cuts Stake in Halozyme Therapeutics
Congress Asset Management Co. reduced its stake in Halozyme Therapeutics, Inc. by 9.4% in the fourth quarter of 2025, selling 134,353 shares and bringing their total holdings to 1,302,180 shares. This move by the investment management firm could indicate a shift in market sentiment towards the biopharmaceutical company, which specializes in drug delivery technologies like its ENHANZE platform. Further analysis is needed to understand the full implications for Halozyme's stock and future outlook.
Interim CFO at Halozyme (NASDAQ: HALO) files initial Form 3 ownership
Halozyme Therapeutics, Inc. (NASDAQ: HALO) Interim CFO David A. Ramsay has filed an initial Form 3, an administrative disclosure recognizing his insider status. The filing details his position as Interim CFO but does not indicate any beneficial ownership of securities or equity transactions as of the report date, reflecting a neutral impact and sentiment. This Form 3 establishes his requirement to report future equity ownership and transactions to the SEC.
HALOZYME THERAPEUTICS, INC. ($HALO) President and CEO 2025 Pay Revealed
HALOZYME THERAPEUTICS, INC. ($HALO) President and CEO Helen I. Torley's 2025 compensation is estimated at $23,166,223, a 45.0% increase from 2024. This information comes from a recent SEC DEF14A filing. The article also details insider trading activity, institutional holdings changes, analyst ratings (all "Buy"), and recent price targets for HALO stock.
Executive pay, board elections lead Halozyme (NASDAQ: HALO) 2026 proxy
Halozyme Therapeutics, Inc. has issued its 2026 definitive proxy statement for an online-only annual stockholder meeting on May 5, 2026. Stockholders are asked to vote on the election of two Class I directors, an advisory say-on-pay resolution for named executive officers, and the ratification of Ernst & Young LLP as auditor. The proxy details performance-based executive compensation, emphasizing strong financial results in 2025 including record revenue and significant stock price growth, and includes information on a one-time performance-based equity award for the CEO.
[ARS] HALOZYME THERAPEUTICS, INC.... | HALO SEC Filing - Form ARS
This article reports on an ARS SEC filing by HALOZYME THERAPEUTICS, INC. (HALO) on March 23, 2026. The filing indicates a low impact and neutral sentiment. It provides links to view the full PDF document and the original filing on SEC EDGAR, along with company news and other recent SEC filings.
Halozyme Touts $1.8B Revenue Outlook, Expanding Subcutaneous Drug Delivery
Halozyme Therapeutics anticipates $1.7 billion to $1.8 billion in total revenue for the current year, driven by strong performance of its ENHANZE subcutaneous drug delivery platform. The company expects royalties from ENHANZE-enabled products to reach $1.1 billion to $1.2 billion and highlighted new ENHANZE and Hypercon deals. Halozyme's technology enables more convenient drug administration, improving patient experience and market access for its partners' biologic therapies.
Halozyme declines after Q4 bottom line miss, reiterates 2026 guidance
Halozyme Therapeutics' shares (NASDAQ:HALO) declined after reporting a Q4 bottom-line miss, despite exceeding revenue expectations. The company reiterated its financial guidance for 2026, projecting revenue between $900M-$1B and adjusted EPS of $7.50-$8.00, driven by its ENHANZE platform.
HALO: Future Upside Will Rely On Expanding ENHANZE And Hypercon Deals
Halozyme Therapeutics (HALO) is seeing a mixed sentiment from analysts, with some raising price targets due to strong Q4 results, higher royalty expectations, and expanding ENHANZE and new licensing deals. However, concerns remain regarding lower royalty rates on new deals like Entyvio, long-term royalty forecasts due to biosimilar competition, and the need for continued progress in next-generation subcutaneous technologies. The company's future growth largely depends on expanding its ENHANZE and Hypercon partnerships.
What Has Caused Halozyme Therapeutics (HALO) Shares to Fall 13.1% Following Its Most Recent Earnings Report?
Halozyme Therapeutics (HALO) shares have dropped 13.1% following its Q4 2025 earnings report, which showed an adjusted loss of $0.24 per share due to an expense related to the Surf Bio acquisition, despite a 52% revenue increase to $451.8 million. The company reaffirmed its 2026 financial outlook, projecting significant growth in revenue, adjusted EBITDA, and EPS, driven by increased royalty income and product sales. Analysts have generally raised their estimates for Halozyme, which currently holds a Zacks Rank #3 (Hold).
Why Is Halozyme Therapeutics (HALO) Down 13.1% Since Last Earnings Report?
Halozyme Therapeutics (HALO) shares have dropped 13.1% since its last earnings report, underperforming the S&P 500. The company reported a fourth-quarter 2025 adjusted loss, missing analyst estimates, despite a 52% year-over-year revenue increase driven by higher royalty revenues. Investors and analysts are now evaluating if this negative trend will continue or if a breakout is expected before the next earnings release, while the company maintains a "Hold" rating from Zacks.
Halozyme (HALO) loses 9% on weak earnings
Halozyme (HALO) shares fell 9% following an earnings report that missed analyst expectations. Despite the Q4 revenue coming in at $214.2 million, it was slightly below the $214.7 million consensus. The company also provided a softer-than-expected revenue forecast of $885 million to $935 million for 2026, leading to investor disappointment.
Alliancebernstein Reduces Stake in Halozyme Therapeutics
Alliancebernstein L.P. has reduced its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 22.3% during the third quarter of 2026, selling 547,913 shares. This reduction signifies a potential shift in market sentiment or outlook for the biopharmaceutical firm, which specializes in drug delivery technologies. Despite continued interest in Halozyme's platform, the move by this significant institutional investor suggests some uncertainty regarding the company's future prospects.
Could Halozyme (HALO) Returning David Ramsay as Interim CFO Reframe Its ENHANZE Royalty Story?
Halozyme Therapeutics has appointed David Ramsay as interim CFO, a move that is seen more as continuity than a significant change in its investment narrative, which is heavily tied to ENHANZE-driven royalty growth. While Ramsay's return brings experience, the company's focus remains on executing against its 2026 revenue guidance and managing risks like patent disputes and partner concentration. Halozyme's forecast projects substantial revenue and earnings growth by 2028, with a fair value estimate of $84.50 per share.
Aquatic Capital Management LLC Acquires Shares of 89,651 Halozyme Therapeutics, Inc. $HALO
Aquatic Capital Management LLC has purchased a new position of 89,651 shares in Halozyme Therapeutics (NASDAQ:HALO) for approximately $6.58 million, representing about 0.08% of the company. Institutional investors collectively own around 97.8% of Halozyme's stock. The company recently reported an EPS miss but a significant revenue increase, while analysts have mixed ratings, ranging from Hold to Sell.
Brevan Howard Sells Stake in Halozyme Therapeutics
Brevan Howard Capital Management LP has significantly reduced its stake in Halozyme Therapeutics, Inc. by over 60% during the third quarter, now owning 64,217 shares. This move suggests a potential shift in the hedge fund's investment strategy or outlook on the biopharmaceutical company, which could influence market sentiment. Halozyme Therapeutics specializes in drug delivery technologies for subcutaneous administration of biologic therapies.
Aquatic Capital Management Buys Stake in Halozyme Therapeutics
Aquatic Capital Management LLC has acquired 89,651 shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO), a biopharmaceutical company specializing in drug delivery technologies. This $6.575 million investment, representing about 0.08% ownership, signifies growing institutional interest in Halozyme's ENHANZE® technology platform and its potential to enhance patient access to biologic therapies. The purchase was made during the third quarter, making Aquatic Capital Management a new investor in the company.
Halozyme appoints David Ramsay as interim CFO
Halozyme Therapeutics has appointed David Ramsay as its interim Chief Financial Officer, effective immediately. Ramsay previously served as the company's Senior Vice President, Investor Relations and Corporate Communications. He will continue to oversee these areas in addition to his new interim CFO responsibilities.
Halozyme Therapeutics (HALO) Valuation Check After Recent Share Price Pullback
Halozyme Therapeutics (HALO) has experienced a recent share price pullback, prompting a re-evaluation of its valuation. While a fair value estimate suggests the stock is undervalued at $84.50 compared to its current price of $63.56, its P/E ratio at 23.7x is above the industry average, indicating potential valuation risk. Investors are advised to consider these mixed signals and conduct further research into the company's fundamentals and risks.
Is Halozyme Therapeutics (HALO) Pricing Look Interesting After Recent Share Price Volatility
Halozyme Therapeutics (HALO) has experienced recent share price volatility, with declines over the last week and month, but significant returns over three and five years. A Discounted Cash Flow (DCF) analysis suggests the stock is 69.7% undervalued at US$63.66, while its P/E ratio of 23.71x indicates it is overvalued compared to its fair ratio and industry averages. The article presents bull and bear case narratives for Halozyme, with different fair value estimates based on assumptions about revenue growth and risk factors.
Halozyme Therapeutics Receives 'Hold' Rating from Analysts
Halozyme Therapeutics, Inc. (NASDAQ:HALO) has received a split "Hold" rating from analysts, with an average 12-month price target of $78.56. The biopharmaceutical company, known for its drug-delivery technologies, faces uncertainty regarding its future performance, reflecting in the mixed analyst recommendations of one 'Sell', five 'Hold', and six 'Buy' ratings. Investors are advised to closely monitor the company's financials, pipeline, and competitive landscape.
Halozyme Therapeutics (HALO) Valuation Check After Recent Share Price Pullback
Halozyme Therapeutics (HALO) has experienced a recent share price pullback, with the stock down 4% in a day and 21% over the past month, leading investors to re-evaluate its valuation. While Simply Wall St's narrative suggests the stock is 24.8% undervalued with a fair value of $84.50 due to an expanding market for biologic therapies, its P/E ratio at 23.7x indicates potential valuation risk compared to the industry average. The article advises investors to assess the mixed signals, considering both key rewards and warning signs associated with the company.
David Ramsay returns as interim CFO at Halozyme (HALO)
Halozyme Therapeutics has appointed David Ramsay as Interim Chief Financial Officer, effective March 23, 2026, while the company searches for a permanent CFO. Ramsay previously served as Halozyme’s CFO for multiple periods and has over 30 years of financial leadership in biotechnology. He will receive a monthly salary of $50,000 and an equity grant of 10,000 restricted stock units, with an additional 2,500 RSUs if he remains in the role past July 1, 2026.
HALO Stock Price, Quote & Chart | HALOZYME THERAPEUTICS INC (NASDAQ:HALO)
This article provides a comprehensive overview of Halozyme Therapeutics Inc. (NASDAQ: HALO), including its current stock price, performance metrics, technical and fundamental analysis ratings, and earnings information. HALO's stock closed at $63.66, showing a slight increase today but a decrease over the past month. Analysts forecast a significant price increase and strong EPS and revenue growth for the company in the next year.
Halozyme Taps David Ramsay as Interim Chief Financial Officer
Halozyme Therapeutics has appointed David Ramsay as Interim Chief Financial Officer, effective March 23, 2026, while the search for a permanent CFO is ongoing. This marks Ramsay's third tenure overseeing Halozyme's financial operations, having previously served from 2003-2009 and 2013-2015, during which he helped transition the company from a private entity to a billion-dollar public pharmaceutical company. CEO Dr. Helen Torley highlighted Ramsay's deep understanding of Halozyme and extensive capital markets expertise as valuable assets during this interim period.
Halozyme Names David Ramsay Interim Chief Financial Officer
Halozyme Therapeutics has appointed David Ramsay as Interim Chief Financial Officer, effective March 23, 2026. Ramsay, a former CFO for the company, will oversee financial operations during the search for a permanent successor, bringing over 30 years of biotechnology finance experience. His return is expected to ensure financial continuity and maintain investor confidence while the company pursues its strategic goals.
Halozyme Therapeutics, Inc. Appoints David Ramsay as Interim Chief Financial Officer, Effective March 23, 2026
Halozyme Therapeutics, Inc. has announced the appointment of David Ramsay as Interim Chief Financial Officer, effective March 23, 2026. Mr. Ramsay, who has over 30 years of strategic financial leadership experience in the biotechnology sector and previously served as Halozyme's CFO from 2003-2009 and 2013-2015, will oversee all financial operations during the search for a permanent CFO. The company has engaged an executive search firm to find a suitable candidate with capital markets expertise and strategic capabilities.
